4hyf
From Proteopedia
(Difference between revisions)
(2 intermediate revisions not shown.) | |||
Line 1: | Line 1: | ||
==Structural basis and SAR for OD 270, a lead stage 1,2,4-triazole based specific Tankyrase1/2 inhibitor== | ==Structural basis and SAR for OD 270, a lead stage 1,2,4-triazole based specific Tankyrase1/2 inhibitor== | ||
- | <StructureSection load='4hyf' size='340' side='right' caption='[[4hyf]], [[Resolution|resolution]] 2.80Å' scene=''> | + | <StructureSection load='4hyf' size='340' side='right'caption='[[4hyf]], [[Resolution|resolution]] 2.80Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'>[[4hyf]] is a 3 chain structure with sequence from [ | + | <table><tr><td colspan='2'>[[4hyf]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4HYF OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4HYF FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=1AK:4-{5-[(E)-2-{4-(2-CHLOROPHENYL)-5-[5-(METHYLSULFONYL)PYRIDIN-2-YL]-4H-1,2,4-TRIAZOL-3-YL}ETHENYL]-1,3,4-OXADIAZOL-2-YL}BENZONITRILE'>1AK</scene>, <scene name='pdbligand=NCA:NICOTINAMIDE'>NCA</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.8Å</td></tr> |
- | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=1AK:4-{5-[(E)-2-{4-(2-CHLOROPHENYL)-5-[5-(METHYLSULFONYL)PYRIDIN-2-YL]-4H-1,2,4-TRIAZOL-3-YL}ETHENYL]-1,3,4-OXADIAZOL-2-YL}BENZONITRILE'>1AK</scene>, <scene name='pdbligand=NCA:NICOTINAMIDE'>NCA</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | |
- | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4hyf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4hyf OCA], [https://pdbe.org/4hyf PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4hyf RCSB], [https://www.ebi.ac.uk/pdbsum/4hyf PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4hyf ProSAT]</span></td></tr> | |
- | + | ||
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | + | |
</table> | </table> | ||
== Function == | == Function == | ||
- | [ | + | [https://www.uniprot.org/uniprot/TNKS2_HUMAN TNKS2_HUMAN] Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, telomere length and vesicle trafficking. Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination and subsequent degradation. Also mediates poly-ADP-ribosylation of BLZF1 and CASC3, followed by recruitment of RNF146 and subsequent ubiquitination. Mediates poly-ADP-ribosylation of TERF1, thereby contributing to the regulation of telomere length. May also regulate vesicle trafficking and modulate the subcellular distribution of SLC2A4/GLUT4-vesicles.<ref>PMID:11802774</ref> <ref>PMID:11739745</ref> <ref>PMID:19759537</ref> <ref>PMID:21478859</ref> |
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
Line 23: | Line 21: | ||
==See Also== | ==See Also== | ||
- | *[[Poly (ADP-ribose) polymerase|Poly (ADP-ribose) polymerase]] | + | *[[Poly(ADP-ribose) polymerase 3D structures|Poly(ADP-ribose) polymerase 3D structures]] |
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
- | [[Category: | + | [[Category: Homo sapiens]] |
- | [[Category: Drewes | + | [[Category: Large Structures]] |
- | [[Category: Ekblad | + | [[Category: Drewes G]] |
- | [[Category: Holsworth | + | [[Category: Ekblad B]] |
- | [[Category: Krauss | + | [[Category: Holsworth DD]] |
- | [[Category: Morth | + | [[Category: Krauss S]] |
- | [[Category: Perdreau | + | [[Category: Morth JP]] |
- | [[Category: Schueler | + | [[Category: Perdreau H]] |
- | [[Category: Voronkov | + | [[Category: Schueler H]] |
- | [[Category: Waaler | + | [[Category: Voronkov A]] |
- | + | [[Category: Waaler J]] | |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + |
Current revision
Structural basis and SAR for OD 270, a lead stage 1,2,4-triazole based specific Tankyrase1/2 inhibitor
|
Categories: Homo sapiens | Large Structures | Drewes G | Ekblad B | Holsworth DD | Krauss S | Morth JP | Perdreau H | Schueler H | Voronkov A | Waaler J